- Home
- MRK vs FCNCP Comparison
MRK vs FCNCP Comparison
Compare MRK & FCNCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRK | FCNCP |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.8B | N/A |
| IPO Year | 1995 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MRK | FCNCP |
|---|---|---|
| Price | $143.59 | $18.12 |
| Analyst Decision | Buy | |
| Analyst Count | 28 | 0 |
| Target Price | ★ $154.62 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 11.1K |
| Earning Date | 10-29-2026 | N/A |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 8.01 | N/A |
| EPS | N/A | ★ 97.95 |
| Revenue | ★ $65,011,000,000.00 | $9,541,000,000.00 |
| Revenue This Year | $3.29 | N/A |
| Revenue Next Year | $4.59 | N/A |
| P/E Ratio | ★ N/A | $0.19 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $82.01 | $18.35 |
| 52 Week High | $157.00 | $22.60 |
Technical Indicators
Market Signals| Indicator | MRK | FCNCP |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 13.59 |
| Support Level | $142.32 | N/A |
| Resistance Level | $153.19 | $21.39 |
| Average True Range (ATR) | 3.19 | 0.29 |
| MACD | -0.73 | -0.11 |
| Stochastic Oscillator | 18.84 | 1.06 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About FCNCP First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of around $237 billion as of June 30, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.